New heart pump trial offers hope for End-Stage heart failure patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * (1) Age ≥ 18 years. * (2) The patient or legal representative has signed the Informed Consent Form (ICF). * (3) Body Surface Area (BSA) ≥ 1.0 m\^2. * (4) Females of childbearing age must agree to use adequate contraception. * (5) Patients with NYHA Class IV heart failure symptoms who have failed to be reversed by previous standardized oral treatment with anti-heart failure drugs (ACEI, beta-blockers, and diuretics). * (6) Left Ventricular Ejection Fraction (LVEF) ≤ 30%, and at least one of the following conditions occurs: * a. Fail to be reversed by or be weaned from intra-aortic balloon pump (IABP), extracorporeal membrane oxygenator (ECMO), or other short-term mechanical circulatory support; * b. Rely on continuous intravenous administration of one or more vasoactive or inotropic drugs; * c. Meeting the diagnostic criteria of cardiogenic shock: blood pressure \< 90/60mmHg, cardiac index \< 2.0 L/min/m\^2, and pulmonary capillary wedge pressure \> 18mmHg. Exclusion Criteria: * (1) Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy pericardial disease, amyloidosis, or restrictive cardiomyopathy. * (2) Presence of an active, uncontrolled infection confirmed by a combination of clinical symptoms and laboratory tests. * (3) Technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator. * (4) Intolerance to anticoagulant or antiplatelet therapies or any other peri/postoperative therapy the investigator will require based on the patient's health status. * (5) Patients require bi-ventricular assist device support. * (6) Pregnancy. * (7) Presence of moderate to severe aortic insufficiency or a history of the mechanical aortic valve that will not be converted to a bioprosthesis or oversewn at the time of implantation. * (8) History of any organ transplantation. * (9) Presence of uncorrected thrombocytopenia or severe coagulopathy, such as diffuse intravascular coagulation. * (10) TBIL (total bilirubin) \> 3.0 mg/dL, serum creatinine (SCr) \> 3.0 mg/dL within 48 hours prior to LVAD implantation surgery or may require dialysis. * (11) History of severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease or a diagnosis of primary pulmonary hypertension. * (12) Pulmonary embolism and pulmonary artery systolic blood pressure exceeding 60mmHg within 3 weeks prior to enrollment combined with at least one of the following 2 parameters demonstrating that pulmonary vascular resistance did not respond to drug therapy: Pulmonary vascular resistance greater than 8 wood units; The transpulmonary differential pressure exceeds 20mmHg. * (13) Established and untreated abdominal or thoracic aortic aneurysm \> 5cm in diameter. * (14) Presence of severe peripheral vascular disease with resting pain or extremity ulceration. * (15) Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and Left Ventricular Assist System management, or brain death from various causes. * (16) Expect to live less than 1 year due to malignant tumor or other diseases. * (17) Participation in any other clinical trials that may influence the results of this study. * (18) Other circumstances that are unforeseen and determined by the researcher to be unsuitable.